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Abstract
Background: Enterovirus and herpes simplex viruses are common causes of lymphocytic meningitis. The purpose
of this study was to analyse the impact of the use molecular testing for Enteroviruses and Herpes simplex viruses I
and II in all suspected cases of viral meningitis.
Methods: From November 18, 2008 to November 17, 2009 (phase II, intervention), all patients admitted with
suspected viral meningitis (with pleocytosis) had a CSF sample tested using a nucleic acid amplification test (NAAT).
Data collected during this period were compared to those from the previous one-year period, i.e. November 18,
2007 to November 17, 2008 (phase I, observational), when such tests were available but not routinely used.
Results: In total, 2,536 CSF samples were assessed, of which 1,264 were from phase I, and 1,272 from phase II. Of
this total, a NAAT for Enterovirus was ordered in 123 cases during phase I (9.7% of the total phase I sample) and in
221 cases in phase II (17.4% of the total phase II sample). From these, Enterovirus was confirmed in 35 (28.5%,
35/123) patients during phase I and 71 (32.1%, 71/221) patients during phase II (p = 0.107). The rate of diagnosis of
meningitis by HSV I and II did not differ between the groups (13 patients, 6.5% in phase I and 13, 4.7% in phase II)
(p = 1.0), from 200 cases in phase I and 274 cases in phase II.
Conclusions: The number of cases diagnosed with enteroviral meningitis increased during the course of this study,
leading us to believe that the strategy of performing NAAT for Enterovirus on every CSF sample with pleocytosis is
fully justified.
Background
Acute meningitis is a frequent syndrome encountered in
emergency rooms. Enteroviruses (EV) accounts for 80%
to 85% of all cases and are the most common pathogens
associated with this disease, but bacterial agents such as
Neisseria meningitidis, Streptococcus pneumoniae and
Haemophilus influenzae are also common agents associ-
ated with this clinical picture. It is very important to
achieve a rapid etiologic diagnosis to differentiate viral
and bacterial meningitis so as to guide the introduction
of antibiotic therapy early or avoid its unnecessary use
for viral diseases. Among EV, Coxsackie and Echovirus
are the predominant serotypes, infecting young adults
and children primarily [1-5].
Other viruses may be associated with lymphomonocytic
meningitis, such as the mumps virus (Paramyxoviridae).
In adults, arboviruses may also be found, occurring in
specific geographic regions, often as epidemic outbreaks
(Saint Louis encephalitis, La Crosse virus, Jamestown
Canyon, etc.) [6].
Although they account for only 0.5% to 3% of all cases
of lymphomonocytic meningitis, meningitis and/or men-
ingoencephalitis caused by Herpes simplex (HSV) I and
II are even more important owing to their potential
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clinical severity in the case of meningoencephalitis, and
the potential for therapeutic intervention [1].
The preferred diagnostic test to identify the etiology of
viral meningitis, especially by EV and HSV 1/2, is the nu-
cleic acid amplification test or NAAT. The advantages of
this test, whether using polymerase chain reaction (PCR)
or nucleic acid sequence-based amplification (NASBA),
are its high sensitivity, quick results and potential to de-
termine the need for antiviral treatment [1,4,7].
In most cases, the clinician must differentiate between
viral and bacterial meningitis because the high mortality
rates and serious sequelae associated with acute bacterial
meningitis require the start of antimicrobial treatment
before culture results are available. The antimicrobial
treatment of bacterial meningitis may last 7 to 21 days.
The need for resampling cerebrospinal fluid (CSF) de-
pends primarily on the patient’s response [8].
The performance of a NAAT for EV and HSV 1/2 can
help clinicians to determine the best approach in each
case, avoiding unnecessary intravenous antibiotics, lum-
bar punctures, side effects from hospitalization, and may
reduce the hospital stay of patients with meningitis,
when a definite diagnosis of viral (and not bacterial)
meningitis is made [1,7,9-11].
The purpose of the present study was to analyse the
impact of the use molecular testing (NAAT) for EV and
HSV 1/2 in all suspected cases of viral meningitis seen
at the Hospital Israelita Albert Einstein (HIAE) and
compare the results with a previous period when those
tests were available but not requested routinely.
Methods
Study site and period
The study was conducted at Hospital Israelita Albert
Einstein (HIAE) and its satellite units providing emer-
gency care, in the city of São Paulo, in the time period
from November 18, 2008 to November 17, 2009 (phase 2,
intervention). At the start of the study CSF sample collec-
tion for Enterovirus and Herpes virus 1 and 2 NAAT was
routinely implemented for all patients with suspected
viral meningitis seen at the emergency units of HIAE.
We developed lectures (four education sessions during
the study period) and a viral meningitis protocol for physi-
cians, principally the infectious diseases physicians, neu-
rologists, pediatricians and emergency medicine doctors.
This educational program was reinforced through the
Continuing Medical Education (CME) Office. Per the
protocol, all CSF samples were tested for cell count, pro-
tein, glucose, Gram stain, and bacterial culture. All CSF
samples with ≥4 WBCs/mm3 were automatically tested
for EV and HSV 1/2 via NAAT. Data collected in this
period were compared to those from the one-year period
before this routine was implemented, i.e. November 18,
2007 to November 17, 2008 (phase 1, observational). In
phase 1, the patient’ physician decided which patient
might have viral meningitis, and ordered the EV and HSV
1/2 NAATs on a case by case basis.
In phase 2, all patients admitted with suspected viral
meningitis were included, irrespective of their age. Pa-
tients were excluded from the study if they had normal
CSF cellularity (less than 4 cells/mm3) and clinical
chemistry parameters, such as glucose, protein, chloride
and lactate, which ruled out meningitis, or if they had
bacterial meningitis documented by a positive gram stain
or latex test.
The case report form included epidemiologic data (gen-
der, age, suspected diagnosis, number of lumbar puncture
attempts), clinical data (signs and symptoms, such as
headache, nausea and/or vomiting, neck stiffness,
temperature, photophobia), prior use of medications (cor-
ticosteroids, immunosuppressive drugs, antimicrobials),
laboratory data (hemoglobin and hematocrit, WBC, plate-
let count, sodium, potassium, creatinine, BUN, blood glu-
cose, alkaline phosphatase, C-reactive protein, CSF
analysis, detection of Enterovirus and Herpes virus by
NAAT), and date of hospital discharge .
Methodology
The institution’s molecular biology laboratory used the
NASBA (Nucleic Acid Sequence Based Amplification)
methodology. The detection of Enterovirus and Herpes
simplex 1 and 2 was performed with Nuclisens EasyQ
kits (Biomérieux, Marcy-l′Etoile, France) specific for
these pathogens, following the manufacturer’s instruc-
tions. A 1-mL sample of CSF was obtained from each
patient. Nucleic acids were extracted using the EasyMag
equipment and then submitted to amplification using
the NucliSENS EasyQ® HSV 1/2 and NucliSENS EasyQ®
Enterovirus kits. The HSV 1/2 kit has probes labeled
with different fluorophores, which identify and differen-
tiate HSV1 from HSV2. The kit for Enterovirus, has
probes that detect preserved regions across the different
serotypes of Enterovirus, including Polio 1–3, Coxsackie
A2-12, A15-18, A20, A21, A24, Coxsackie B1-6, Echo-
virus 1–9, 11–15, 17–21, 24–27, 29–33, and Enterovirus
68–71. In terms of analytic sensitivity, the 50% and 95%
exhaustive coefficients have been determined to be 93
and 263 copies per nucleic acid extract, respectively.
This means that a sample at concentrations of 93 and
263 copies per nucleic extract will be detected with a
positivity rate of 50 and 95% respectively when exhaust-
ively tested. Both kits also have a probe to detect an in-
ternal control, monitoring the quality of the process
from the extraction phase.
During phase I, molecular analyses were performed only
3 days a week, and the turnaround time was approxi-
mately 24 hours. In phase II, NAAT for EV and HSV 1/2
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was available 7 days per week, 24-hours per day and the
target time to release the result was 12 hours.
Statistical analysis
Continuous variables were compared using the Student’s
t test if they showed a normal distribution, and the
Mann–Whitney test if they did not. Differences in pro-
portions were compared using the Pearson’s chi-square
test or the Fisher exact test, as appropriate. Mean values
were reported ± 1 standard deviation. The p value was
defined as 0.05 and all tests with statistical significance
were two-tailed. All statistical analyses were developed
using the Statistical Package for the Social Sciences soft-
ware (SPSS, Chicago, IL, USA,11.5).
Informed consent exemption
The present study was approved by the Ethics Committee
of HIAE. Considering that the NAAT is routinely per-
formed in the hospital, and that the study included only
the recording of laboratory data and a search in medical
records, our institutional review board waived the need
for written informed consent from the participants.
Results
In total, 2,536 CSF samples were assessed, of which
1,264 were from the pre-study period (phase I) and
1,272 from the post-study period (phase II). Of this total,
a NAAT for EV was ordered in 123 cases during phase I
(9.7% of the total phase I sample) and in 221 cases in
phase II (17.4% of the total phase II sample). From these,
EV was confirmed in 35 patients during phase I and 71
patients during phase II (p = 0.107). The diagnosis of
meningitis by HSV 1 and 2 did not differ between the
groups (13 patients in phase I and 13 in phase II) (p =
1.0), from 200 cases in phase I and 274 cases in phase II
(Table 1).
Among those patients with viral meningitis (either by
EV or by HSV 1/2- see Table 2), 52.1% in phase I and
36.9% in phase II were females (p = 0.9). The mean age of
the patients was 20.0 years (SD 16.4) in phase I and
17.5 years (SD 17.3) in phase II (p = 0.43). The number of
specimens by age was for EV: 0–5 years (46.2%, 49/106),
6–17 years (24.5%, 26/106), 18+ years (29.3%, 31/106); and
for HSV1/2: 0–5 years (no cases), 6–17 years (3.8%, 1/26 -
-one case for HSV 1), 18+ years (96.2%, 25/26 – 25 cases
for HSV 2). In phase I 23.4% and in phase II 14.3% had
some comorbidity (p = 0.19). The mean number of days of
hospitalization was 2.9 (SD 2.6) in phase I and 2.7 (SD 3.9)
in phase II (p = 0.69).
In the group of patients with viral meningitis due to
EV or HSV 1/2 (Table 2), the most commonly found
symptoms included: headache (93.3% in phase I and
92.6% in phase II) (p > 0.99), nausea and vomiting (66.7%
vs. 70.4%) (p = 0.66), fever (77.8% vs. 67.9%) (p = 0.24)
and neck stiffness (42.2% vs. 49.4%) (p = 0.44).
CT scans were performed on 45.8% of the patients in
phase I and 49.4% of the patients in phase II (p = 0.69);
in phase I, 14.6% received antibacterial treatment versus
22.6% in phase II (p = 0.26) (Table 2). However, the anti-
bacterial treatment duration was less than 24 hours in
78.3% of the cases of meningitis due to EV.
Concerning CSF characteristics, in phase I, 77.1%
showed predominantly lymphomonocytic cellularity at
the first sampling versus 65.1% in phase II (p = 0.15).
The WBC results showed a median of 162.5 and an
interquartile range (IQR) of 85–350 in phase I versus
118 and 59.5-313.5 in phase II (p = 0.174) (Table 2). In
about 10% of cases (in both phases), the number of leu-
kocytes in the first CSF sample exceeded 500 cells per
mm3. The glucose, protein and lactate levels in the CSF
were quite similar in both groups. In none of them were
bacteria detected by gram stain, latex agglutination, or a
positive culture.
When we analyzed only the subgroup with meningitis
by EV (Table 3), we found that the mean hospital stay was
2.4 days (SD 2.3) in phase 1 versus 1.9 days (SD 2.4) in
phase 2 (P = 0.25). A lymphomonocytic pleocytosis in the
CSF was 71.4% in phase 1 and 59.2% in phase 2 (P = 0.21).
The number of patients treated with antibacterials was 6
(17.1%) in phase 1 versus 18 (25.4%) in phase 2 (P = 0.34).
However, there was no record of the duration of antibi-
otics use, only whether or not they were used.
After phase II, we have continued to monitor the
number of EV meningitis cases over the years, and the
number of diagnosed cases increased gradually reaching
30% (72/242) in 2009, 27% (71/260) in 2010, 46% (112/
242) in 2011 and 48% (56/116) in the first half of 2012
(Table 4).
Discussion
EV infections are common in children and adults, even
though children are more susceptible to infection [1,12].
Table 1 Results of nucleic acid amplification testing
(NAAT)
Variables Phase 1 Phase 2 Total
Lumbar punctures performed 1,264 1,272 2,536
NAAT performed for Enterovirus 123 221 344
NAAT performed for Herpes virus 1 and 2 200 274 474
Viral meningitis cases ( Enterovirus + Herpes
virus 1 and 2)
48 84 132
Meningitis by Enterovirus – n (%)* 35 (73) 71 (84) 106 (80)
Meningitis by Herpes virus 1 and 2 - n (%)** 13 (27) 13 (16) 26 (20)
*p-value = 0.107.
**p-value = 1.0.
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They may cause several diseases such as conjunctivitis,
upper and lower respiratory tract infections, meningitis,
encephalitis, encephalomyelitis and acute flaccid paraly-
sis [3,7,13].
Enteroviruses belong to the Picornaviridae family,
consist of a single strand of RNA [13], and include Cox-
sackie viruses A and B, Echovirus, and Poliovirus, among
others, totaling more than 80 serotypes [1-3,13]. Some
of these serotypes are more closely associated with men-
ingitis than others [13].
EV Transmission occurs mainly through the fecal – oral
route, but the oral – oral and the respiratory routes are
also possible [2,14]. The most common form of CNS in-
fection is through viremia, with some serotypes exhibiting
more marked neurotropism or neurovirulence [2].
Approximately 80 to 90% of all cases of aseptic menin-
gitis, in which a pathogen is identified, are enteroviruses.
[1,2,4,7,10,11,13] When we analyze the adult population
(>16 years of age), EV infection appears in about 40% of
the cases of aseptic meningitis followed by HSV-2 and
VZV (17% each), EBV (12%), HSV-1, and mumps virus
(7% each) [15]. The varicella-zoster virus seems to be
underestimated as a cause of aseptic meningitis and en-
cephalitis [5].
In Brazil, Santos et al. have shown that Echovirus 30
was the most frequently agent isolated from CSF sam-
ples of patients with viral meningitis [14].
In most enteroviral infections, the incubation period
ranges from 3 to 10 days [2], and several viruses caus-
ing meningitis have a seasonal distribution, with a
Table 2 Sample including Enterovirus and HSV 1/2
Phase 1 Phase 2 P value
n % n %
Gender Female 25 52.1 31 36.9 0.09
Male 23 47.9 53 63.1
Meningitis Herpes 13 27.1 13 15.5 0.10
Enterovirus 35 72.9 71 84.5
Presence of any comorbidity 11 22.9 12 14.5 0.19
Headache 42 87.5 75 92.6 0.99
Nausea and vomiting 30 62.5 57 70.4 0.66
Fever (T > 37.7°C) 35 72.9 55 67.9 0.24
Stiff neck 19 39.6 40 49.4 0.44
Predominant cellularity in 1st CSF sample Neutrophilic 11 22.9 29 34.9 0.15
Lymphomonocytic 37 77.1 54 65.1
Result of NAAT for Enterovirus Negative 12 25.5 13 15.5 0.02
Positive 35 74.5 71 84.5
Result of NAAT for Herpes simplex Negative 29 60.4 64 76.2 0.18
Positive for HSV type I 1 2.1 0 0
Positive for HSV type II 12 25 13 15.5
Predominant cellularity in 2nd CSF sample Neutrophilic 0 0 0 0 ***
Lymphomonocytic 7 100 7 100
Use of antibacterials to treat meningitis 7 14.6 19 22.6 0.264
Underwent imaging exam (brain) 22 45.8 41 49.4 0.694
Phase 1 Phase 2 P value
Mean SD Mean SD
Age (years) 20.0 16.5 17.5 17.3 0.43
Length of hospital stay (days) 2.9 2.6 2.7 4.0 0.69
Time from symptom onset to admission 2.13 2.23 1.60 1.26 0.08
Leukocytes in 1st CSF sample (n/mm3) 262.9 259.6 205.2 217.7 0.17
Neutrophils in 1st CSF sample (%) 29.9 28.5 38.3 29.2 0.11
Lymphocytes in 1st CSF sample (%) 50.3 28.3 43.9 28.2 0.21
***testing not possible.
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Table 3 Demographic data of patients with meningitis due to Enterovirus
Phase 1 Phase 2 P value
N = 35 % N = 71 %
Gender Female 14 40 19 26.8 0.16
Male 21 60 52 73.2
Presence of any comorbidity 8 23.5 5 7 0.02
Headache 29 90.6 63 92.6 0.70
Nausea and vomiting 30 66.7 57 70.4 0.66
Fever > 37.7°C 26 81.3 50 73.5 0.39
Stiff neck 13 40.6 32 47.1 0.54
Predominant cellularity in 1st CSF sample Neutrophilic 10 28.6 29 40.8 0.21
Lymphomonocytic 25 71.4 42 59.2
Predominant cellularity in 2nd CSF sample Neutrophilic 0 0 0 0 ***
Lymphomonocytic 4 100 3 100
Use of antibacterials to treat meningitis 6 17.1 18 25.4 0.34
Underwent imaging exam (brain) 13 37.1 29 40.8 0.71
Phase 1 Phase 2 P value
Mean SD Mean SD
Age (years) 12.5 11.7 12.5 12.8 0.98
Length of hospital stay (days) 2.4 2.3 1.9 2.4 0.25
Time from symptom onset to admission 2.34 2.55 1.58 1.28 0.10
Leukocytes in 1st CSF sample (n/mm3) 254.9 262.5 184.5 208.5 0.13
Neutrophils in 1st CSF sample (%) 38.7 27.3 43.9 27.8 0.36
Lymphocytes in 1st CSF sample (%) 40.2 23.1 37.5 24.6 0.58
***testing not possible.
Table 4 Number of cases with positive result for Enteroviruses from January 2008 to June 2012
Month 2008 2009 2010 2011 2012
Total Positive Total Positive Total Positive Total Positive Total Positive
n % n % n % n % n %
January 10 6 60 8 1 13 16 5 31 14 3 21 6 1 17
February 16 3 19 13 4 31 13 3 23 15 7 47 12 5 42
March 18 5 28 16 5 31 16 2 13 26 15 58 18 9 50
April 3 1 33 21 8 38 21 7 33 26 15 58 35 24 69
May 15 2 13 22 9 41 23 6 26 24 12 50 23 11 48
June 15 3 20 24 7 29 26 3 12 15 10 67 22 6 27
July 5 1 20 24 7 29 29 8 28 18 4 22 - - -
August 8 2 25 17 3 18 18 6 33 16 4 25 - - -
September 5 1 20 10 4 40 22 9 41 15 7 47 - - -
October 10 5 50 27 5 19 25 11 44 26 15 58 - - -
November 25 11 44 21 6 29 27 5 19 17 7 41 - - -
December 13 6 46 39 13 33 24 6 25 30 13 43 - - -
Total 143 46 32 242 72 30 260 71 27 242 112 46 116 56 48
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predominance in summer and autumn [11,16], a pat-
tern we have not observed in our sample.
Symptoms vary depending on the affected age range
and include headache, fever, irritability, stiff neck, photo-
phobia, nausea and vomiting [1-3,11,13,14].
The most commonly used diagnostic methods include
CSF analysis, culture, serology, and nucleic acid amplifi-
cation [1,3]. Establishing a definite diagnosis is important
to reduce the hospitalization period and the use of antibi-
otics [1,17] and these are reasons favoring the diagnosis
of viral meningitis by molecular methods (NAAT).
The CSF analysis in viral meningitis usually reveals
predominantly mono-morphonuclear pleocytosis, more
often between 100 and 300 leukocytes/mm3, normal or
slightly elevated protein, and normal glucose [1,2]. How-
ever, there seems to be different CSF patterns depending
on the pathogen involved [15]. The CSF may show up to
1,000 leukocytes per mm3, mainly polymorphonuclear
cells, in the earlier phases of the disease, making diagno-
sis even more difficult [1,2,7,10].
Graham and Murdoch have shown that more than half
of the patients with pleocytic CSF had a polymorpho-
nuclear pattern, despite a confirmed viral etiology [17].
However, the diagnosis of EV meningitis is often made
in the absence of pleocytosis or increased levels of pro-
tein, especially in children [1,2,9,17].
Culture is the most traditional method [9], but EV take
from 4 to 8 days to grow in cell culture, therefore the cul-
ture can seldom contribute to the patient’s management
[1,11]; its use, therefore, is no longer recommended and
has been abandoned in routine laboratory practice [18]. In
addition, it has low sensitivity and must be performed by
highly qualified personnel [7,11]. Many patients with men-
ingitis by EV are hospitalized and treated with parenteral
antibiotics until they show clinical improvement and nega-
tive cultures after 48 hours of incubation [7].
Serological methods are currently used to confirm infec-
tion during outbreaks caused by a single serotype of EV
[1]. A minimum 4-fold increase in antibody titers is neces-
sary between the acute and convalescent phases [2]. The
quantitative interpretation of a single serum sample is of
no value, since there is great variation between the titers
for different serotypes in healthy subjects. Considering
that there are more than 60 antigenically different sero-
types without shared antigens, serological techniques are
not very practical [2].
On the other hand, nucleic acid amplification tech-
niques allow for a quick diagnosis of enteroviral infec-
tions [1,7,9] and represent the best diagnostic method
available at present [7,10,12]. Different commercial kits
are currently available; they require a small sample vol-
ume, show higher sensitivity than viral culture, have
100% specificity, [1,2,4,18] and their cost is similar to
that of a culture [7]. Over the study period, our
laboratory worked with the only molecular technique for
EV available on the market, the Nuclisens system for
specific amplification of viral RNA using the NASBA
methodology [19]. Since NAAT shows positivity well be-
fore viral cultures, it allows the reduction of unnecessary
hospitalization as well as diagnostic and therapeutic in-
terventions, especially in documented cases of enterovi-
ral meningitis [1,4,7,10,11].
However, in many centers, NAAT is not available on a
daily basis to the point that some patients admitted dur-
ing weekdays remained in hospital one day less and used
less antibiotics when compared to those admitted during
the weekend [10]. At the beginning of the present study,
molecular analyses were performed only 3 days a week,
at the approximate cost of $175, and the turnaround
time was approximately 24 hours. At present, PCR for
enterovirus is available at our hospital 7 days a week, 24-
hour a day and the target time to release the result is
12 hours, at an approximate cost of $85. This has in-
creased the routine use of this technology.
Studies show that whenever NAAT results for Entero-
virus are available, hospitalization can be reduced by at
least 12 to 24 hours, which in turn significantly reduces
the costs. Other previously reported benefits include a
shorter stay in inpatient care units, fewer requests for
computerized tomography, magnetic resonance imaging,
and electroencephalograms, as well as shorter-term anti-
biotic therapies [1,9,10]. Our data failed to show these
same results, however this may have been due to inad-
equate sample size. Unnecessary antibiotic use and the
corresponding increase in bacterial resistance rates are
topics of interest in the approach to EV meningitis [1].
The ability to detect and quickly differentiate EV-
associated diseases from those related to other viruses
and/or bacteria represents a critical target from the thera-
peutic, prognostic and epidemiologic points of view [14].
Since 2008, when our hospital started to implement
NAAT for EV, the number of diagnosed cases increased
gradually reaching 112 positive results from 242 suspect
cases (46.3% of the sample) in 2011 (Table 4). The number
of diagnosed cases practically doubled, while the same was
not observed with HSV, highlighting the benefits of using
NAAT on a routine basis. It is also worth mentioning that
our study failed to show any reduction in hospitalization
time or exposure to antimicrobial therapy, since our sam-
ple included only those patients with a documented diag-
nosis of viral meningitis. During phase 1, it is possible that
patients with enteroviral meningitis not promptly diag-
nosed by the usual methods received antibiotics for a few
days, have undergone repeat spinal tap and have remained
in hospital for longer than necessary, simply due to the ab-
sence of a documented viral diagnosis.
We are aware of the fact that, at present, there is no ef-
fective antiviral therapy for EV, and management is limited
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to symptomatic measures [2,4,11,16]. Most cases resolve
spontaneously, [11,16] usually in less than 7 days [1], but
the molecular diagnosis of meningitis by EV and HSV 1/2
is beneficial in many ways. It reduces the use of antibacte-
rials and their associated risks, shortens hospitalization, al-
lows for fewer lumbar punctures, helps reduce parental
anxiety about the diagnosis and the likelihood of a bacterial
infection and, saves costs for the hospital and the family.
This study had several limitations. This study was a
protocol for improving viral meningitis diagnosis in our in-
stitution. It was performed at a single medical center, and
thus our findings might not be generalizable to other hospi-
tals. We did not create a prompt during the interventional
phase (phase II) for clinicians to order both tests (EV and
HSV). Pediatricians generally asked only EV and not HSV
for children. We had also patients with meningoencephal-
itis or with encephalitis for whom EV was not performed.
This is one of the reasons for the differences between the
number of EV and HSV 1/2 tests ordered. One other limi-
tation was that we may have missed cases because we re-
quired pleocytosis for testing for EV or HSV 1/2.
The mere fact that the number of cases diagnosed with
EV meningitis increased by almost 100% during the im-
plementation of this protocol leads us to believe that the
strategy of performing NAAT for EV on every CSF sam-
ple is extremely important.
Conclusion
Based on this study, our hospital decided to implement
the strategy and also to use it as a quality indicator.
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